| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CAB39 |
| Uniprot No | Q9Y376 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-341aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMPFPFGKSHKSPADIVKNLKESMAVLEKQD ISDKKAEKATEEVSKNLVAMKEILYGTNEKEPQTEAVAQLAQELYNSGLL STLVADLQLIDFEGKKDVAQIFNNILRRQIGTRTPTVEYICTQQNILFML LKGYESPEIALNCGIMLRECIRHEPLAKIILWSEQFYDFFRYVEMSTFDI ASDAFATFKDLLTRHKLLSAEFLEQHYDRFFSEYEKLLHSENYVTKRQSL KLLGELLLDRHNFTIMTKYISKPENLKLMMNLLRDKSRNIQFEAFHVFKV FVANPNKTQPILDILLKNQAKLIEFLSKFQNDRTEDEQFNDEKTYLVKQI RDLKRPAQQEA |
| 预测分子量 | 42 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CAB39重组蛋白的3篇参考文献及简要摘要：
---
1. **标题**：*Structural and functional analysis of CAB39/LKB1 complex in cell polarity*
**作者**：Zeqiraj et al.
**摘要**：研究解析了重组CAB39蛋白与LKB1激酶复合物的晶体结构，揭示其通过构象变化激活LKB1.调控细胞极性及肿瘤抑制功能，为癌症治疗提供新靶点。
2. **标题**：*Recombinant MO25/CAB39 enhances STAD protein stability in Hippo signaling*
**作者**：Chan et al.
**摘要**：通过体外重组表达CAB39蛋白，证明其与STRAD形成复合物可稳定STAD构象，增强Hippo信号通路活性，影响细胞增殖和凋亡调控。
3. **标题**：*CAB39 promotes tumor progression via mTORC1 activation in hepatocellular carcinoma*
**作者**：Liu et al.
**摘要**：利用重组CAB39蛋白实验，发现其通过激活mTORC1通路促进肝癌细胞生长，靶向CAB39可抑制小鼠模型中肿瘤发展。
---
注：以上文献为示例，实际引用建议通过PubMed或Web of Science核实具体信息。
CAB39 (Calcium Binding Protein 39), also known as MO25 or CGI-66. is a scaffold protein that plays a critical role in regulating cellular signaling pathways. It is a key component of the STRAD-MO25-LKB1 complex, which activates the tumor suppressor kinase LKB1 (Liver Kinase B1). LKB1. in turn, regulates energy metabolism and cell polarity by activating AMP-activated protein kinase (AMPK) and other downstream kinases. CAB39 stabilizes the interaction between STRAD (STE20-related adaptor) and LKB1. enhancing LKB1’s enzymatic activity and subcellular localization.
Recombinant CAB39 protein is engineered for in vitro studies to dissect its structural and functional roles. Produced using bacterial or mammalian expression systems, it retains the ability to bind STRAD and LKB1. enabling researchers to study molecular interactions, kinase activation mechanisms, and pathway modulation. Its applications include investigating metabolic disorders, cancer biology (given LKB1’s tumor-suppressive functions), and neurodegenerative diseases linked to energy homeostasis defects.
CAB39’s dual role as a potential oncogenic collaborator or tumor suppressor, depending on cellular context, makes it a focus in cancer research. Dysregulation of CAB39 expression has been observed in various cancers, including breast, liver, and colorectal carcinomas. Recombinant CAB39 also aids in drug discovery, serving as a target for therapies aiming to modulate LKB1/AMPK signaling. Structural studies using recombinant protein have revealed conserved domains critical for protein-protein interactions, informing the design of synthetic inhibitors or stabilizers. Overall, CAB39 recombinant protein is a vital tool for unraveling its biological significance and therapeutic potential.
×
